Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)

AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety
Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Category & Conditions:
Cancer
Medicine:
Xtandi (enzalutamide)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C3431010
Open Plain Language Summary Result:Click here